Bloomberg’s viral misquote : Columbia Journalism Review

/bloombergs_viral_misquote_1.php

  • Bloomberg’s viral misquote : Columbia Journalism Review
    http://www.cjr.org/the_audit/bloombergs_viral_misquote_1.php?page=all

    That quote sounded a little too perfectly evil, and I couldn’t find the original anywhere online. So I asked Bayer whether Bloomberg had it wrong. They did.

    Here’s what Dekkers actually said, at a Financial Times conference that day, on a panel called “Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust” (the above link leads to video of the panel and the relevant part starts at about 19:00 in):

    “Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product.

    mais :

    Agence France Presse, as far as I could find, was the only outlet that fact-checked the quote with Bayer, and even then the system broke down.
    Bayer said the statements attributed to Dekkers were accurate and forwarded written comments made later by the German chief executive seeking to explain his remarks.

    et Bloomberg a corrigé avec la mention :

    (Corrects last paragraph to show Dekkers said “Indian market” and include full quote.)

    http://www.bloomberg.com/news/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-patents.html

    cf. http://seenthis.net/messages/220303

    • on a enfin une transcription complète : du coup on découvre la suite de la citation, qui fait aussi froid dans le dos

      Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar | Knowledge Ecology International
      http://keionline.org/node/1924

      So now, is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. I mean, you know, we developed this product for western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product. But you know the risk in these situations is always spillover. If this generic Indian company is now going to sell this product, then South Africa, and then New Zealand, you never know, you know, how this is going to spillover. And that puts the whole industry and the patent right of an industry at risk.